Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Sponsored by Regeneron Pharmaceuticals
About this study
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Where this study is enrolling (3)
- Call (713) 484-6947
Clinical Trial Network, LLC
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- Call (713) 779-5494
Juno Research, LLC
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
Prolato Research LLC
Houston, Texas
Who can participate
Inclusion criteria
- ✓1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
- ✓2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
- ✓3. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
- ✓4. Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening
Exclusion criteria
- ✕1. Known medical history or clinical evidence indicative of non-diabetic renal disease
- ✕2. Renal disease that required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or kidney transplantation
- ✕3. Medically unstable as assessed by the investigator or hospitalization (ie, \>24 hours) within 30 days of the screening visit
- ✕NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.